Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies

Cariprazine, a potent dopamine D(3) and D(2) receptor partial agonist antipsychotic with preferential binding to D(3) receptors, is Food and Drug Administration approved for treating schizophrenia and manic or mixed episodes of bipolar I disorder. A post-hoc safety/tolerability analysis of data from...

Descripción completa

Detalles Bibliográficos
Autores principales: Earley, Willie, Durgam, Suresh, Lu, Kaifeng, Laszlovszky, István, Debelle, Marc, Kane, John M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams And Wilkins 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625952/
https://www.ncbi.nlm.nih.gov/pubmed/28692485
http://dx.doi.org/10.1097/YIC.0000000000000187

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625952/
https://www.ncbi.nlm.nih.gov/pubmed/28692485
http://dx.doi.org/10.1097/YIC.0000000000000187

Ejemplares similares